The past 5–10 years have brought in a new era in the care of patients with thyroid cancer,
with the introduction of transformative diagnostic and management options. Several …

Over the past 15 years, rapid progress has been made in developmental therapeutics,
especially regarding the use of matched targeted therapies against specific oncogenic …

A concerted commitment across research stakeholders is necessary to increase equity,
diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and …

PURPOSE Hematopoietic cell transplantation (HCT) is curative for hematologic disorders,
but outcomes are historically inferior when using HLA-mismatched donors. Despite …

Importance Disadvantaged neighborhood-level and individual-level socioeconomic status
(SES) have each been associated with suboptimal cancer care and inferior outcomes …

Background Improving diversity in clinical trials is essential in order to produce
generalizable results. Although the importance of representation has become increasingly …

Integrating Research into Community Practice Many strategies have been developed to
increase enrollment of diverse populations in clinical trials, but they have produced mixed …

Purpose Despite clear evidence-based supporting a benefit to exercise on physical and
psychological metrics in patients with cancer, recruitment to exercise trials amongst cancer …

Importance Logistical challenges such as travel time and distance to a clinical trial site can
be a barrier to patient participation. The association of remote technology use and other …

Background Racial and ethnic minorities (REMs) continue to be underrepresented in clinical
trials despite the 1993 National Institutes of Health's Revitalization Act mandating the …